CriticalProkinetic, 5-HT4 serotonin receptor agonist (withdrawn EU/US)×Non-selective beta blocker with class III antiarrhythmic activity
Updated · Methodology
Mechanism
Sotalol prolongs the QT interval and can cause torsade de pointes, more often at higher doses, with a slow heart rate, with low potassium or magnesium and with other QT-prolonging drugs (sotalol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish sotalol SmPC names cisapride among drugs that induce torsade de pointes and states that, given with sotalol, they raise the risk of ventricular arrhythmias (sotalol SmPC, AEMPS). According to the erythromycin SmPC, high blood levels of cisapride can prolong the QT interval and cause arrhythmias, including ventricular tachycardia, ventricular fibrillation and torsade de pointes (erythromycin SmPC, AEMPS). Sotalol is not metabolised and is not expected to inhibit or induce cytochrome P450 enzymes (sotalol label, US Food and Drug Administration, FDA), so the documents do not describe any rise in cisapride levels caused by sotalol.
Symptoms
QT prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). Torsade de pointes causes palpitations, dizziness and fainting and may stop on its own or, in rare cases, progress to ventricular fibrillation. With sotalol it usually appears soon after the start of treatment or a dose increase (sotalol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). High cisapride levels can cause ventricular tachycardia, ventricular fibrillation and torsade de pointes (erythromycin SmPC, AEMPS). Sotalol also slows the heart rate, and a slow heart rate itself raises the risk of torsade de pointes (sotalol SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish sotalol summary of product characteristics (SmPC) contraindicates sotalol with QT-prolonging drugs and names cisapride both in the contraindications section and in the list of contraindicated combinations (sotalol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Cisapride is not in the Spanish medicines register CIMA and has no current US prescribing information, so the severity rating follows the sotalol SmPC. If a person takes cisapride obtained in another country, do not prescribe sotalol with it (sotalol SmPC, AEMPS). The US sotalol label also says to avoid use with QT-prolonging drugs (sotalol label, US Food and Drug Administration, FDA). Start sotalol and increase its dose in a setting where heart rhythm can be monitored. Before that, record an electrocardiogram (ECG) with QT measurement and assess kidney function, electrolytes and all current medicines. Correct low potassium or magnesium before the first dose (sotalol SmPC, AEMPS). If during sotalol treatment QRS or QT lengthens by 25% or more, PQ by 50% or more, or the corrected QT interval (QTc) exceeds 480 ms, reassess benefit and risk and seriously consider a lower dose or withdrawal (sotalol SmPC, AEMPS). Do not stop sotalol abruptly: reduce the dose gradually over one to two weeks, especially in ischaemic heart disease (sotalol SmPC, AEMPS). Treat torsade de pointes caused by excess sotalol with direct-current (DC) cardioversion, transvenous pacing, adrenaline and/or magnesium sulfate (sotalol SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Betapace / Betapace AF (sotalol hydrochloride) tablets – prescribing information (2024)– FDA label, Legacy Pharma USA, DailyMed setid a6a7702f-36c9-45db-b640-453dc324baee, version 2, 12/2024, sections 4, 5.1 and 7.1
- AEMPS: Ficha técnica: Sotapor (sotalol) (nº registro 62001), sección 4.3 (2022)– AEMPS, CIMA, nº registro 62001, revisión 11/2022, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Eritromicina (nº registro 55771), sección 4.5 (2025)– AEMPS, CIMA, nº registro 55771 (Pantomicina 1 g polvo para solución para perfusión, Amdipharm), revisión 09/2025 (texto revisado 02/2023), secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Sotalol, Sotapor 80 mg (nº registro 62001), sección 4.5 (2022)– AEMPS, CIMA, nº registro 62001 (Sotapor 80 mg comprimidos, Cheplapharm), revisión 11/2022 (texto revisado 09/2022), secciones 4.3, 4.4, 4.5 y 5.2